Sun to launch breast cancer therapy in India, upbeat on US prospects
This article was originally published in Scrip
Executive Summary
Sun Pharma Advanced Research Company (SPARC) has outlined progress made by its pipeline products, including paclitaxel injection concentrate for nanodispersion (PICN) and latanoprost plus timolol once daily ophthalmic solution, both of which have now been approved in India. SPARC is the listed spin-off R&D arm of Sun Pharma of India.